View Cart (0 items)
Food & Beverage

FDA to review Schering-Plough schizophrenia tablet

November 26, 2007
/ Print / Reprints /
| Share More
/ Text Size+
Drug developer Schering-Plough Corp. is seeking marketing approval from the Food and Drug Administration for a tablet used to treat schizophrenia and bipolar disorder, the Associated Press reports. Schering-Plough said the FDA accepted the new drug application of asenapine for a standard review. Schering-Plough acquired asenapine through its buyout of Organon BioSciences NV earlier this month. The clinical trial program for the drug has so far consisted of schizophrenia.
You must login or register in order to post a comment.

Related Events